---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-100794"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:46:16.529925+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NextCure Q2 net loss $18M; cash $249.5M; trials NC318/NC410/NC762 on track

## Summary
- Net loss of $18.0M for Q2 2021 vs $14.5M in Q2 2020; R&D $11.9M, G&A $6.0M.
- Cash, equivalents & marketable securities $249.5M as of June 30, 2021; funded into H2 2023.
- NC318 Phase 2 update expected Q4 2021; dosing revised to 800 mg weekly; NSCLC cohort resumed.
- NC410 initial Phase 1 data expected Q4 2021; NC762 Phase 1 started, data mid-2022.
- CLIA-validated assay for S15+ patient selection available for NC318 trial.

## SEC filing metadata
- accession: 0001104659-21-100794
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465921100794/0001104659-21-100794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465921100794/tm2124228d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-100794
- JSON: https://secwatch.observer/filing/0001104659-21-100794.json
- Plain text: https://secwatch.observer/filing/0001104659-21-100794.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.